Dr. Levy joined the Naegis Board in June 2013, bringing her extensive leadership experience in the biotechnology industry and in drug development. In addition to being founder of QLT Inc., Dr Levy held several key senior posts at QLT including Chief Scientific Officer and Vice President as well as President and CEO from 1995 to February 2002. Dr. Levy served as Director of QLT from 1983 to 2006. Under her leadership, QLT recorded the strongest period of growth in company history and earned a reputation for achieving milestones, including FDA approval for Visudyne® therapy to treat age-related blindness in April 2000. Following her doctorate degree in Immunology from the University of London, Dr. Levy was awarded an industrial Professorship in the Department of Microbiology from the University of British Columbia and is the recipient of several honorary degrees. A fellow of the Royal Society of Canada and former President of the Canadian Federation of Biological Sciences, Dr. Levy has earned numerous awards and honors, including an appointment as an Officer of the Order of Canada in 2001, the Female Entrepreneur of the Year for International Business in 1998, Pacific Canada Entrepreneur of the Year in 2000 and the Future of Vision Award from the Foundation Fighting Blindness in 2001.